David Kaslow, MD, is our vice president for Essential Medicines, which includes our Drug Development Program and the PATH Center for Vaccine Innovation and Access (CVIA). As the director of CVIA, he leads our work to accelerate the development and introduction of lifesaving vaccines for the most vulnerable children and communities around the world.
Dr. Kaslow has more than 25 years of experience in vaccine research and development. Before joining PATH in 2012 as director of MVI's work to drive the development of safe and effective vaccines against malaria, he held key advisory positions with MVI and the Bill & Melinda Gates Foundation related to malaria vaccines. Prior to that, he oversaw project leadership and management of Merck Research Laboratories’ vaccine pipeline and founded the Malaria Vaccine Development Unit at the National Institutes of Health.
As a basic research scientist, Dr. Kaslow completed the molecular cloning and characterization of several proteins involved in malaria parasite sexual development. He also has directed product development, including field studies, of several malaria vaccine candidates. Outside the malaria field, Dr. Kaslow has contributed to the vaccine application of tools originally developed for gene therapy. He holds or coholds more than a dozen patents and has published more than 150 scientific papers.
Dr. Kaslow received his medical degree from the University of California, San Francisco.